SignPost was accepted into Newchip’s renowned global accelerator program. Designed to provide all the skills and tools seed-stage founders need to rapidly fund, build and scale their companies, past accelerator cohorts averaged more than 17.5 times the average funding amount.

“Newchip evaluates a vast and diverse number of seed-stage companies from around the globe, selecting only a small percentage to be part of our Seed Accelerator program,” says Brian Lee, Head of Product at Newchip. “This careful vetting process of both the business model and founder makes us an ideal partner for venture capital investors and other key stakeholders in early-stage startup financings who are looking for promising startups that are beginning to generate traction and revenue.  Life Science companies like SignPost can scale quickly with proper funding and guidance. We are excited for SignPost and believe they will be well positioned to take advantage of our fast-expanding global ecosystem at Newchip.”

 

 

GENEVA (Reuters) –Breast cancer has overtaken lung cancer as the most common form of the disease, accounting for nearly 12% of new cases each year worldwide, the World Health Organization said on Tuesday.

“For the first time, breast cancer now constitutes the most commonly occurring cancer globally,” Andre Ilbawi, a cancer specialist at the WHO, told a U.N. briefing ahead of World Cancer Day on Thursday.

Lung cancer was the most common type for the last two decades, but is now in second place, ahead of colorectal cancer, which is the third most widespread, Ilbawi said.

An estimated 2.3 million new cases of breast cancer were diagnosed last year, representing 11.7% of all cancer cases, the WHO said in a statement. “Among women, breast cancer is the most commonly-diagnosed cancer and the leading cause of cancer death worldwide,” it said.

January 7, 2021 – Ontario, Canada – SignPost Cancer Dx Inc. (“SignPost” or “company”), a company developing an advanced molecular diagnostic test to identify invasive breast cancer, announced today that Mr. Peter Blaney, Chief Executive Officer, will present at the 2021 BioConnect Conference hosted by H.C. Wainwright. Registered attendees can access the recorded presentation on-demand (24×7) for the duration of the conference.

Conference Date:	January 11-14, 2021 (Monday-Thursday)
Presentation On-Demand:	Starting 6:00am ET – Monday, January 11, 2021
Registration:	https://hcwevents.com/

Mr. Blaney will highlight the company’s lead product, BreastDefense, a molecular diagnostic test to identify invasive breast cancers, from Stage 1-4, with 98.5% accuracy and the company’s strategy going forward.

SignPost will be available for virtual 1:1 meetings both during and after the BioConnect Conference.  Please contact Jennifer K. Zimmons, Ph.D. jzimmons@zimmonsic.com 917.214.3514 for scheduling.

About SignPost Cancer Dx Inc.

SignPost is a company developing an advanced molecular diagnostic test, BreastDefense, to identify invasive breast cancers, from Stage 1-4, with 98.5% accuracy. BreastDefense is being developed in both tissue and liquid biopsy versions.  SignPost was founded and is managed by Induran Ventures, a Venture Philanthropy General Partnership which strives to achieve both outsized returns and massive social impact through its projects.  For more information, please visit www.signpostcancerdx.com.

 

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

 

SignPost Cancer Dx Inc.

Peter Blaney

Chief Executive Officer

SignPost Cancer Dx Inc.

Tel: +1 613.532.1290

Email: peterblaney@induranventures.com

 

Investor Contact:

Jennifer K. Zimmons, Ph.D.

Investor Relations

Zimmons International Communications
Tel: +1 917.214.3514

Email: jzimmons@zimmonsic.com

 Source: SignPost Cancer Dx Inc.

###

 

Dear Friends, As the holiday season begins, we hope that this update finds you and your family safe and healthy.  With 2020 coming to a close, we wanted to take the time to review several positive milestones, advancements, and achievements as well as highlight new opportunities that are on the horizon for 2021. The summary below reviews the highlights, turning points, and milestones of 2020. 1.   Hired US Investor Relations Professional To increase corporate visibility, SignPost engaged Zimmons International Communications, Inc. (ZIC). Jennifer K. Zimmons, PhD specializes in working with emerging companies and focuses on communications and corporate outreach to family offices, high net-worth investors, and boutique healthcare funds.  Dr. Zimmons is also the Chair of the Program Committee for Women in Bio (New York).  Over the summer and into the fall, ZIC has been involved with: arranging introductions to various types of family offices, boutique investors, and strategic parties; creating various investor materials and press releases; and identifying presentation opportunities for SignPost to highlight the company and its science.     i.       Featured Speaker and Presenter at Women In Bio’s October  Breast Cancer Awareness Panel In October, SignPost was featured in Women In Bio’s (WIB) online event entitled “Females Pioneering Accurate Breast Cancer Detection and Innovative Ways of Healing”.  WIB is an international group with over 10,000 members committed to highlighting females in the life sciences and in companies’ instrumental in supporting women’s health. ii.        Women of Influence and Strategic Introductions As we round out the year, we remain focused on identifying women of influence in the investment and healthcare areas.  Based on recent outreach efforts, we feel individuals with the aforementioned profile are ideally positioned to be supporters for BreastDefense and for investment and board positions.   2.   Filed Provisional Patent In July 2020, SignPost filed its provisional patent for the company’s lead diagnostic test – BreastDefense.  The patent is for the DNA Methylation Multivariate Biomarkers offering 98.5% specificity and sensitivity (false positives and false negatives).  Having the provisional patent in place is a very significant milestone for SignPost. The provisional patent allows SignPost to more openly share critical information with development partners, investors, and strategic entities.   3.   The Cancer Screening Marketplace The cancer screening marketplace saw some big deals this year. Earlier in September, the biotech firm, Illumina, announced it will buy back cancer-detection start-up GRAIL, Inc.  in an $8 billion deal.  GRAIL is developing a blood-based cancer test called Galleri™, a medical test that can detect dozens of types of cancer.  While GRAIL is developing a “pan-cancer diagnostic”, from published reports, we believe SignPost has developed a more accurate test specifically for breast cancer where our specificity and sensitivity is better than 98.5%. In late October 2020, Exact Sciences (Nasdaq: EXAS) announced the intention to buy Thrive Earlier Detection, a private blood-based, multi-cancer screening company.  The transaction was comprised of cash and stock consideration of up to $2.15 billion. 4.   Why Companies Such as SignPost are Critical to Advancing Cancer Treatment Therapies Dr. Azra Raza talks with Dr. Peter Attia about her new book The Cell in the following podcast.  Take a listen as Dr. Raza discusses the content of her book which takes a critical look at survival rates of cancer for patients (a study of novel cancer treatment outcomes from 2000 to 2016 only increased survival by 2.4 months!)  and why early detection is the way forward. It is a fascinating podcast.  The key times discussing early detection are at 29min-31min and 1hr:24min -1hr:40min. In closing, we want to thank you for your continued interest in SignPost.  As you can see, there are many opportunities that we look forward to exploring in 2021.  We wish the best in safety and health for you and your family during this holiday season. Peter Blaney Chief Executive Officer SignPost Cancer Dx Inc. Tel: +1 613.532.1290 E: peterblaney@induranventures.com Investor and Press Contact: Jennifer K. Zimmons, Ph.D. Investor Relations Zimmons International Communications Tel: +1 917.214.3514 Email: jzimmons@zimmonsic.com Source: SignPost Cancer Dx Inc. ###

 

Take a listen to Peter Attias interview with Dr. Raza .

Peter Attia is a Canadian-American physician of Egyptian descent known for his medical practice that focuses on the science of longevity. He is also the first person to make the round-trip swim from Maui and Lanai.

Dr. Azra Raza is a physician, scientist, author, and outspoken advocate for reconfiguring the current model of research in cancer. In this episode, Azra discusses the content of her book, The First Cell, which takes a critical look at the outdated models being used to study cancer resulting in a lack of progress in survival rates for cancer patients. Azra offers a solution which focuses on early detection and prevention, and she concludes with an optimistic outlook for the future of cancer research.

If you have limited time the early detection discussion is at 29min and 1.22min in. However the entire interview is fascinating.